Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant Tumors
ConditionNeoplams
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorMabsoft Therapeutics (Shanghai) Co., Ltd.
About this trial
A Phase 1, multiregional, open-label study of MST-168 in participants with target-driven advanced solid tumors.
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic effects, and preliminary efficacy of MST-168 in participants with target-driven advanced solid tumors. MST-168 is an investigational ADC.
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- MST-168
Treatment groups
420 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Locations
Sponsors and collaborators
Mabsoft Therapeutics (Shanghai) Co., Ltd.
Lead sponsor
Mabsoft Therapeutics (Australia) Pty. Ltd.
Collaborator
Mabsoft Therapeutics (Guangdong Hengqin) Co., Ltd.
Collaborator
Source ClinicalTrials.gov